Core Viewpoint - The report discusses the development and market potential of HDAC/PI3Kα dual-target inhibitors, highlighting their mechanisms, current market status, and future prospects in the pharmaceutical industry. Group 1: Mechanism and Importance - PI3K is a crucial enzyme in the PI3K-Akt-mTOR signaling pathway, which is significant in cancer, immune response, and thrombosis control [3][4] - HDACs play a vital role in gene expression regulation and chromatin structure modification, with abnormal acetylation levels linked to cancer and immune diseases [4][5] - The combination of HDAC and PI3K inhibitors shows synergistic anti-tumor effects, enhancing therapeutic efficacy against various cancers [5][6] Group 2: Market Status - As of June 30, 2025, only BEBT-908 has been approved for market, while several PI3K inhibitors have been approved in China, including Duvelisib and Lymphocil [7][8] - The approved HDAC inhibitors in China include Vorinostat and Entinostat, with specific indications for various cancers [8] Group 3: Research and Development - Ongoing clinical trials for PI3K and HDAC inhibitors include drugs like Aibestatin and Puyisitan, targeting relapsed or refractory diffuse large B-cell lymphoma [9][10] - The report outlines the current R&D status of these inhibitors, indicating a growing pipeline in the oncology sector [10][11] Group 4: Industry Analysis - The report provides a comprehensive analysis of the economic, policy, social, and technological environments affecting the HDAC/PI3Kα dual-target inhibitor industry in China [10][11] - It also discusses the competitive landscape, market structure, and future trends in the industry, emphasizing the importance of multi-target pharmacology [5][6][10]